CJC-1295 with ipamorelin and GHRP-2
CJC-1295 (with DAC) with ipamorelin and GHRP-2
Written by Aaron CuhaReviewed Sep 2026
Also known as: Triple GH blend, CJC/IPA/GHRP-2
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
Three growth hormone peptides in one vial, usually 2 mg of each. Three sounds better than two. Here is the thing. Two of the three hit the exact same switch. So you are getting two switches, one of them pressed twice. Nobody has tested this mix.
What people take it for
- Better sleep.
- Losing fat and holding muscle.
- Healing faster.
- People who think more ingredients means more effect.
What the trials actually showed
No study has tested three of these together. No study has even tested two peptides at the same switch together. The real combination work paired one GHRP with GHRH by drip, and that beat GHRH alone in healthy older adults. One GHRP was enough to show it. Here is why the third ingredient is a step backwards. Ipamorelin got picked in the first place because it stirs up less cortisol, less prolactin and less hunger than the older ones. GHRP-2 is one of the older ones. A controlled study showed it raises food intake in healthy men. Putting it back in undoes the reason you chose ipamorelin. The math: mix 6 mg with 2 mL and every unit mark carries 10 micrograms of each. Draw 10 units and you took 100 micrograms of each. That is 200 micrograms hitting the hunger switch, and the label never shows it that way.
What people report
Reports, not trial results
The good
- Deep sleep and vivid dreams early on.
The bad
- Strong hunger, which surprises people who picked ipamorelin to avoid it.
- Water retention, puffy hands and carpal tunnel type symptoms, reported more here than on two part blends.
- Flushing after the shot.
- No schedule fits. If the vial holds the long acting GHRH molecule, its half life is 5.8 to 8.1 days while the other two are gone in hours. Daily piles one up. Weekly wastes two.
Where these come from: Peptide and gym forums, seller listings and clinic write-ups. People talking. The hunger effect is backed by a controlled human study of one of the ingredients.
My bottom line
Three names on a label, two mechanisms, one of them doubled. You are paying extra to bring back the side effect the newer peptide exists to avoid.
An opinion, not a finding. I am a coach, not a doctor.
Overview
Three growth hormone secretagogues in one vial, commonly 2 mg each in a 6 mg vial. Two of the three act at exactly the same receptor, which is the fact this product is built to obscure. The combination has never been studied, and adding a second ghrelin-receptor agonist to the first adds the older agent's appetite and cortisol profile without adding a second mechanism.
Three is the number that should stop a buyer. Ipamorelin and GHRP-2 are both agonists at the growth hormone secretagogue receptor, the ghrelin receptor. They are not two mechanisms. They are two drugs at one target, and putting both in a vial is closer to taking a larger dose of one than to combining two different approaches.
That matters because of why ipamorelin exists at all. It was selected within this class for releasing growth hormone with less effect on cortisol and prolactin than the older GHRPs, and GHRP-2 is one of the older GHRPs. A buyer who chose ipamorelin specifically to avoid the appetite, cortisol and prolactin profile of the earlier agents, and then bought a vial containing both, has undone the choice.
The third component is the only genuinely different mechanism in the vial. A GHRH analogue raises pulse amplitude at a separate receptor, and the class evidence for pairing a GHRH agent with a ghrelin-receptor agent is real: a 24 hour infusion of GHRP-2 with GHRH raised growth hormone above either alone in healthy older adults. One GHRP would have delivered that.
Arithmetic on the common 2 plus 2 plus 2 vial. Six milligrams of powder reconstituted with 2 mL gives 3 mg/mL total and 1 mg/mL of each component, so one unit on a 100 unit insulin syringe carries 10 micrograms of each. A 10 unit draw is 100 micrograms of each. Note what happens to the ghrelin arm: at 10 units you have taken 200 micrograms of combined ghrelin-receptor agonist, twice what a single-agent user would call 100 micrograms, and the label never presents it that way.
Some versions of this vial use CJC-1295 with drug affinity complex, whose published half-life is 5.8 to 8.1 days, alongside two agents that clear in hours. That is not a schedule problem you can solve. Dose daily and the long component accumulates for weeks; dose weekly and the two short components are absent for six days out of seven.
Mechanism of action
Two of the three components are agonists at the same growth hormone secretagogue receptor and are additive at that receptor rather than complementary. The third is a GHRH receptor agonist raising pulse amplitude. All three outputs converge on pituitary growth hormone release and then on hepatic IGF-1, so the axis cannot attribute anything to any one component.
Human evidence
No trial of the three together, and no trial of any two ghrelin-receptor agonists given together.
- The blend: no published study, no registration.
- Class combination of a GHRH agent with one GHRP: raised growth hormone beyond either alone in healthy older adults, by infusion.
- Two ghrelin-receptor agonists together: never studied in people, and no mechanistic reason to expect more than a larger dose of one.
- Ipamorelin: one randomised trial, 117 surgical patients, no benefit on its endpoint.
- GHRP-2: raises food intake in healthy men and sustains a raised growth hormone axis over 30 days of infusion.
What this does not tell you: Every endpoint here is a hormone concentration. Nothing in this literature measures the body composition, recovery or aging outcomes the product is sold for.
What it has been measured to do
Measured in people
Goals CJC-1295 with ipamorelin and GHRP-2 has been measured for in a human being, most people first. Counts come from the study lines on this page and deliberately undercount.
- Gut and digestion117 people · 1 study
- Growth hormone and IGF-1no headcount stated · 2 studies
- Feeling less hungryno headcount stated · 1 study
What people using it report
Uncontrolled and self-selected, so it cannot show that anything works. It is still the best guide on this page to what people actually do with CJC-1295 with ipamorelin and GHRP-2, what they expect, and what goes wrong. The full account, including the negative reports, is below.
33 of the 36 indexed goals have no study of any kind behind CJC-1295 with ipamorelin and GHRP-2
No trial, no animal work, no cell work on this page reports a result for these. That is an absence of evidence rather than evidence of absence, but it does mean anything you have been told about CJC-1295 with ipamorelin and GHRP-2 and one of these did not come from a study cited here.
Reading the research record
This vial is the clearest example in the category of component count being used as a proxy for effect. Three ingredients read as more than two on a label. Pharmacologically it is two mechanisms, one of them delivered twice, and the second delivery brings back the appetite and cortisol profile that the newer agent was chosen to avoid.
The half-life spread is the second unsolvable problem. When one component is designed to persist for days and two are gone in hours, the daily schedule that suits the short agents accumulates the long one, and the weekly schedule that suits the long one leaves the short agents unused for most of the week. There is no correct interval for this vial, only a choice about which component to dose wrongly.
The evidence, charted
Fig. 1a · evidence scale
117people, across 1 human study cited here
- 2014 · International Journal of Colorectal Disease117100%
The whole total is one study of 117. Counts are the enrollment each human citation on this page states, which includes observational cohorts where nobody was given the compound. 3 further human citations state no participant count and are not counted here. Studies still recruiting are excluded, and only studies cited on this page are counted.
Fig. 1b · evidence mix
All 4 citations here are human work.
- Human · given to people4100%
Counted from the citation list on this page, typed as this page types it. It understates any literature larger than the sources we cite, and a review counts once however many studies it covers.
Fig. 2 · evidence over time
Evidence spans 4 distinct years, 2004 to 2014, counted from the citation list on this page. The newest citation on file is from 2014, more than five years ago; the published record may have gone quiet.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four jurisdictions shown. A jurisdiction's classification is a regulatory fact, not a verdict on the science; see Legal status below for the full text and any notes.
Fig. 4 · dose response
No human dose response curve exists
We draw this figure where the data supports it. For this compound in humans it does not, so the panel stays empty rather than borrowing an animal curve and implying it transfers.
Fig. 5 · molecular identity
- Modality
- Blend
- Molecular weight
- Not on file
- Half-life
- Stated in words, not a number
- Sequence length
- None on file
see the exact wording below
Half-life as stated on file: Not defined for the blend, and the mismatch is the point. Two components are gone quickly while the third can persist, and the mixture has never been measured.
No amino acid sequence is on file for CJC-1295 with ipamorelin and GHRP-2, which is expected: a blend is not built from residues.
Fig. 6 · what is in the vial
33.3%of a 6 mg CJC-1295 with ipamorelin and GHRP-2 vial is CJC-1295 (with DAC)
- CJC-1295 (with DAC)2 mg33.3%
- Ipamorelin2 mg33.3%
- GHRP-22 mg33.3%
Label mass from a standard vial, not a dose, and not an assay. The ratio is fixed by the seller, so a draw that hits the amount you want of one component sets the amount of every other component with it. No study has tested this combination in any species.
Key studies & citations
- Human2006
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
Single subcutaneous injections in healthy adults raised mean plasma growth hormone two to ten-fold for six days or more and IGF-1 1.5 to three-fold for nine to eleven days, with an estimated half-life of 5.8 to 8.1 days and IGF-1 above baseline for up to 28 days after multiple doses. A component lasting that long shares this vial with two that clear in hours.
Journal of Clinical Endocrinology and Metabolism - Human2004
Sustained elevation of pulsatile growth hormone (GH) secretion and insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and IGFBP-5 concentrations during 30-day continuous subcutaneous infusion of GH-releasing peptide-2 in older men and women
A 24 hour infusion combining a ghrelin-receptor agonist with GHRH raised growth hormone secretion above either agent given alone in healthy older adults. One GHRP was enough to show the two-receptor effect; nothing in this literature supports adding a second agent at the same receptor.
Journal of Clinical Endocrinology and Metabolism - Human2005
Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men
GHRP-2 increased food intake in healthy men. This is the profile ipamorelin was selected to avoid, and it returns to the vial the moment GHRP-2 is added alongside it.
Journal of Clinical Endocrinology and Metabolism - Human2014
Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients
117 bowel resection patients randomised to intravenous ipamorelin or placebo twice daily. Safe, and the key efficacy endpoint of time to tolerating a solid meal was the measure it was tested against. This is the only randomised controlled trial of ipamorelin in people.
International Journal of Colorectal Disease
What users report
Self-reported experiences, not evidence. Nothing below was measured under controlled conditions, and reports like these cannot separate a real effect from placebo, from the training or diet change that accompanied it, or from what the product actually contained. They are here because knowing what people describe, including what goes wrong, is worth reading alongside the studies.
- Strong hunger, which people attribute to the GHRP-2 and which often surprises those who chose ipamorelin to avoid it.
- Deep sleep and vivid dreams early on.
- Water retention, puffy hands and carpal tunnel type symptoms at higher draws, more often than on two-component blends.
- Flushing after injecting.
- Confusion about dosing, because the three components have no shared schedule.
Sources: Peptide and bodybuilding forums, vendor listings and clinic write-ups. Uncontrolled self-reports. The appetite effect has controlled human support for GHRP-2 specifically.
Frequently asked questions
Are ipamorelin and GHRP-2 two different mechanisms?
No. Both are agonists at the growth hormone secretagogue receptor, the ghrelin receptor. Putting both in a vial is closer to a bigger dose of one than to a second mechanism.
Why is that a problem?
Ipamorelin was selected within this class for causing less cortisol, prolactin and appetite effect than the older GHRPs. GHRP-2 is one of the older GHRPs. Adding it back returns the profile ipamorelin exists to avoid.
What does one unit deliver?
On a 6 mg vial with 2 mg of each, reconstituted with 2 mL, each unit mark carries 10 micrograms of each component. A 10 unit draw is 100 micrograms of each, which is 200 micrograms of combined ghrelin-receptor agonist.
How often should this be injected?
There is no interval that fits. If the vial contains the drug affinity complex GHRH analogue, that component has a published half-life of 5.8 to 8.1 days while the other two clear in hours. Daily accumulates one, weekly wastes two.
Has the three-way combination been tested?
No, in any species. The only combination work in this class paired one GHRP with GHRH, by infusion, in a research setting.